Dr. Jeffrey Braverman will become medical director of the new Sher Institute for Reproductive Medicine
As reported on www.send2press.com
GARDEN CITY, NY - July 10 (SEND2PRESS NEWSWIRE) -- The Sher Institute for Reproductive Medicine - New York, part of one of the largest and fastest growing infertility networks in the United States, announces the opening of Sher Institute for Reproductive Medicine-Long Island (SIRM(SM)-Long Island) in partnership with Dr. Jeffrey Braverman.
Located in Garden City, NY, SIRM(SM)-Long Island will have exclusive access on Long Island to breakthrough technology in the field of In Vitro Fertilization (IVF) that has the potential to dramatically increase the odds of a woman getting pregnant through IVF, while at the same time reducing the likelihood of multiple births.
Dr. Jeffrey Braverman, who has been in private practice for over 16 years as an Obstetrician/Gynecologist and Infertility Specialist will assume the role of Medical Director of SIRM(SM)-Long Island. He has personally delivered over 6,000 babies and has overseen thousands of infertility treatment cycles, with an outstanding record of success.
"I'm extremely excited to lead the Sher Institutes' Long Island office," said Dr. Braverman. "This area is home for me, and I look forward to bringing SIRM's longstanding tradition of compassionate care and ongoing medical breakthroughs to the people here. I feel like we have the potential to help so many people in this area that are struggling with infertility."
Dr. Joel Batzofin, Medical Director of SIRM-New York was equally optimistic in his outlook for the Long Island office. "I look forward to working closely with Dr Braverman in helping provide Long Island patients access to cutting edge protocols and technology that are unique to SIRM centers," he said. "I too see tremendous opportunities to help people."
One recent example of this proprietary technology is the subject of several studies by SIRM(SM) Founder Geoffrey Sher, M.D. and Levent Keskintepe Ph.D. of ReproCure, LLC. The studies demonstrate that a new process for the genetic testing of early embryos may help determine which ones are most likely to produce normal pregnancies in IVF patients. This could lead to a major improvement in IVF success rates for practices using this testing method. The current national average pregnancy rate is 30% per treatment cycle in women under 40. Furthermore, the researchers report that these increases can be achieved by transferring no more than one (1) or sometimes two (2) embryos, thereby virtually eliminating the risk of high order multiple births (triplets or greater).
